412 related articles for article (PubMed ID: 25003762)
1. Advances in the management of psoriatic arthritis.
Olivieri I; D'Angelo S; Palazzi C; Padula A
Nat Rev Rheumatol; 2014 Sep; 10(9):531-42. PubMed ID: 25003762
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and safety of the anti-IL-12/23 p40 monoclonal antibody, ustekinumab, in patients with active psoriatic arthritis despite conventional non-biological and biological anti-tumour necrosis factor therapy: 6-month and 1-year results of the phase 3, multicentre, double-blind, placebo-controlled, randomised PSUMMIT 2 trial.
Ritchlin C; Rahman P; Kavanaugh A; McInnes IB; Puig L; Li S; Wang Y; Shen YK; Doyle MK; Mendelsohn AM; Gottlieb AB;
Ann Rheum Dis; 2014 Jun; 73(6):990-9. PubMed ID: 24482301
[TBL] [Abstract][Full Text] [Related]
3. TNF alpha inhibitors in the treatment of psoriasis and psoriatic arthritis.
Tobin AM; Kirby B
BioDrugs; 2005; 19(1):47-57. PubMed ID: 15691217
[TBL] [Abstract][Full Text] [Related]
4. Current evidence in the field of the management with TNF-α inhibitors in psoriatic arthritis and concomitant hepatitis C virus infection.
Caso F; Cantarini L; Morisco F; Del Puente A; Ramonda R; Fiocco U; Lubrano E; Peluso R; Caso P; Galeazzi M; Punzi L; Scarpa R; Costa L
Expert Opin Biol Ther; 2015 May; 15(5):641-50. PubMed ID: 25652590
[TBL] [Abstract][Full Text] [Related]
5. Effects of ustekinumab versus tumor necrosis factor inhibition on enthesitis: Results from the enthesial clearance in psoriatic arthritis (ECLIPSA) study.
Araujo EG; Englbrecht M; Hoepken S; Finzel S; Kampylafka E; Kleyer A; Bayat S; Schoenau V; Hueber A; Rech J; Schett G
Semin Arthritis Rheum; 2019 Feb; 48(4):632-637. PubMed ID: 30037432
[TBL] [Abstract][Full Text] [Related]
6. Review of the treatment of psoriatic arthritis with biological agents: choice of drug for initial therapy and switch therapy for non-responders.
D'Angelo S; Tramontano G; Gilio M; Leccese P; Olivieri I
Open Access Rheumatol; 2017; 9():21-28. PubMed ID: 28280401
[TBL] [Abstract][Full Text] [Related]
7. A review on golimumab in the treatment of psoriatic arthritis.
Urdaneta M; Jethwa H; Sultan R; Abraham S
Immunotherapy; 2017 Sep; 9(11):871-889. PubMed ID: 28838285
[TBL] [Abstract][Full Text] [Related]
8. New targets in psoriatic arthritis.
Braun J
Rheumatology (Oxford); 2016 Dec; 55(suppl 2):ii30-ii37. PubMed ID: 27856658
[TBL] [Abstract][Full Text] [Related]
9. Role of Agents other than Tumor Necrosis Factor Blockers in the Treatment of Psoriatic Arthritis.
Atzeni F; Costa L; Caso F; Scarpa R; Sarzi-Puttini P
J Rheumatol Suppl; 2015 Nov; 93():79-81. PubMed ID: 26523064
[TBL] [Abstract][Full Text] [Related]
10. Minimal Disease Activity and Remission in Psoriatic Arthritis Patients Treated with Anti-TNF-α Drugs.
Perrotta FM; Marchesoni A; Lubrano E
J Rheumatol; 2016 Feb; 43(2):350-5. PubMed ID: 26669925
[TBL] [Abstract][Full Text] [Related]
11. Novel approaches to biological therapy for psoriatic arthritis.
Boyd T; Kavanaugh A
Expert Opin Biol Ther; 2016; 16(2):173-86. PubMed ID: 26572089
[TBL] [Abstract][Full Text] [Related]
12. New Approaches in Tumor Necrosis Factor Antagonism for the Treatment of Psoriatic Arthritis: Certolizumab Pegol.
Cauli A; Piga M; Lubrano E; Marchesoni A; Floris A; Mathieu A
J Rheumatol Suppl; 2015 Nov; 93():70-2. PubMed ID: 26523062
[TBL] [Abstract][Full Text] [Related]
13. Elderly psoriatic arthritis patients on TNF-α blockers: results of an Italian multicenter study on minimal disease activity and drug discontinuation rate.
Costa L; Lubrano E; Ramonda R; Chimenti MS; Vezzù M; Perrotta FM; Del Puente A; Peluso R; Bottiglieri P; Lorenzin M; Sunzini F; Darda MA; Fiocco U; Perricone R; Punzi L; Scarpa R; Caso F
Clin Rheumatol; 2017 Aug; 36(8):1797-1802. PubMed ID: 28589323
[TBL] [Abstract][Full Text] [Related]
14. Two-year survival rates of anti-TNF-α therapy in psoriatic arthritis (PsA) patients with either polyarticular or oligoarticular PsA.
Iannone F; Lopriore S; Bucci R; Scioscia C; Anelli MG; Notarnicola A; Lapadula G
Scand J Rheumatol; 2015 May; 44(3):192-9. PubMed ID: 25564882
[TBL] [Abstract][Full Text] [Related]
15. Effects of polymorphisms in TRAILR1 and TNFR1A on the response to anti-TNF therapies in patients with rheumatoid and psoriatic arthritis.
Morales-Lara MJ; Cañete JD; Torres-Moreno D; Hernández MV; Pedrero F; Celis R; García-Simón MS; Conesa-Zamora P
Joint Bone Spine; 2012 Dec; 79(6):591-6. PubMed ID: 22480748
[TBL] [Abstract][Full Text] [Related]
16. Switching biologics in the treatment of psoriatic arthritis.
Merola JF; Lockshin B; Mody EA
Semin Arthritis Rheum; 2017 Aug; 47(1):29-37. PubMed ID: 28363434
[TBL] [Abstract][Full Text] [Related]
17. The use of TNF-α blockers in psoriatic arthritis patients with latent tuberculosis infection.
Atteno M; Costa L; Matarese A; Caso F; Del Puente A; Cantarini L; Bocchino ML; Sanduzzi A; Scarpa R
Clin Rheumatol; 2014 Apr; 33(4):543-7. PubMed ID: 24554385
[TBL] [Abstract][Full Text] [Related]
18. Tumor necrosis factor inhibitors in psoriatic arthritis.
Mantravadi S; Ogdie A; Kraft WK
Expert Rev Clin Pharmacol; 2017 Aug; 10(8):899-910. PubMed ID: 28490202
[TBL] [Abstract][Full Text] [Related]
19. Effectiveness and safety of adalimumab in patients with ankylosing spondylitis or psoriatic arthritis and history of anti-tumor necrosis factor therapy.
Rudwaleit M; Van den Bosch F; Kron M; Kary S; Kupper H
Arthritis Res Ther; 2010; 12(3):R117. PubMed ID: 20553600
[TBL] [Abstract][Full Text] [Related]
20. Newly available treatments for psoriatic arthritis and their impact on skin psoriasis.
Galadari H; Fuchs B; Lebwohl M
Int J Dermatol; 2003 Mar; 42(3):231-7. PubMed ID: 12653923
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
